DK3295941T3 - Fremgangsmåde til fremstilling af form a af grapiprant - Google Patents

Fremgangsmåde til fremstilling af form a af grapiprant Download PDF

Info

Publication number: DK3295941T3
Authority: DK; Denmark
Prior art keywords: grapiprant; procedure; making
Prior art date: 2014-03-06

Application number

DK17193737.8T

Other languages

English (en)

Inventor

Tamara Newbold

Melissa Smith

Christopher Seekamp

Robert Wenslow

Xia Lu

Original Assignee

Aratana Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-06

Filing date

2015-03-05

Publication date

2020-08-24

2015-03-05 Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc

2020-08-24 Application granted granted Critical

2020-08-24 Publication of DK3295941T3 publication Critical patent/DK3295941T3/da

Links

HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 title 1
229950004517 grapiprant Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Led Devices (AREA)
Ceramic Products (AREA)
Inorganic Insulating Materials (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

DK17193737.8T 2014-03-06 2015-03-05 Fremgangsmåde til fremstilling af form a af grapiprant DK3295941T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461949006P	2014-03-06	2014-03-06
US201461996961P	2014-07-30	2014-07-30
EP15758500.1A EP3113773B1 (en)	2014-03-06	2015-03-05	Crystalline forms of grapiprant

Publications (1)

Publication Number	Publication Date
DK3295941T3 true DK3295941T3 (da)	2020-08-24

Family

ID=54016295

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK17193737.8T DK3295941T3 (da)	2014-03-06	2015-03-05	Fremgangsmåde til fremstilling af form a af grapiprant
DK19156369.1T DK3511000T3 (da)	2014-03-06	2015-03-05	Krystallinsk form x2 af grapiprant
DK15758500T DK3113773T3 (da)	2014-03-06	2015-03-05	Krystallinske former af grapiprant

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK19156369.1T DK3511000T3 (da)	2014-03-06	2015-03-05	Krystallinsk form x2 af grapiprant
DK15758500T DK3113773T3 (da)	2014-03-06	2015-03-05	Krystallinske former af grapiprant

Country Status (16)

Country	Link
US (1)	US9265756B2 (da)
EP (4)	EP3295941B1 (da)
JP (2)	JP6535683B2 (da)
KR (2)	KR101697914B1 (da)
CN (11)	CN107759590A (da)
AU (1)	AU2015227064B2 (da)
CA (10)	CA2997718A1 (da)
DK (3)	DK3295941T3 (da)
ES (3)	ES2755396T3 (da)
MX (2)	MX367376B (da)
NZ (3)	NZ733234A (da)
PL (3)	PL3295941T3 (da)
PT (3)	PT3511000T (da)
RU (1)	RU2638931C1 (da)
TW (1)	TWI537270B (da)
WO (1)	WO2015134797A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3113774T (pt)	2014-03-06	2022-02-28	Elanco Animal Health Incorporated	Composições de grapiprant e métodos de utilização das mesmas
US12109218B2 (en)	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
JP2021522211A (ja)	2018-04-16	2021-08-30	アリーズセラピューティクス，インコーポレイテッド	Ｅｐ４阻害剤およびその使用
US20210300921A1 (en) *	2018-07-11	2021-09-30	Arrys Therapeutics, Inc.	Ep4 inhibitors and synthesis thereof
US20210315909A1 (en) *	2018-07-11	2021-10-14	Arrys Therapeutics, Inc.	Polymorphic compounds and uses thereof
US11254675B2 (en) *	2019-08-12	2022-02-22	Cadila Healthcare Limited	Process for preparation of grapiprant
WO2021226162A1 (en)	2020-05-05	2021-11-11	Arrys Therapeutics, Inc.	Ep4 antagonists and their use in the treatment of proliferative diseases
CN116283959A (zh) *	2021-12-10	2023-06-23	江苏慧聚药业股份有限公司	格拉匹纶新晶型及其制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2001000224A (es)	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2600510C (en) *	2005-03-11	2010-11-02	Pfizer Inc.	Crystal forms of an imidazole derivative
BRPI0611375A2 (pt) *	2005-05-23	2010-08-31	Novartis Ag	formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
AU2007331471C1 (en) *	2006-12-15	2013-07-25	Glaxo Group Limited	Benzamide derivatives as EP4 receptor agonists
JP5536773B2 (ja) *	2008-08-14	2014-07-02	ベータ・ファーマ・カナダ・インコーポレイテッド	Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2012157288A1 (en)	2011-05-18	2012-11-22	Raqualia Pharma Inc.	Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid

2015
- 2015-03-05 CN CN201710832416.3A patent/CN107759590A/zh not_active Withdrawn
- 2015-03-05 ES ES15758500T patent/ES2755396T3/es active Active
- 2015-03-05 MX MX2016011023A patent/MX367376B/es active IP Right Grant
- 2015-03-05 DK DK17193737.8T patent/DK3295941T3/da active
- 2015-03-05 CN CN201710831494.1A patent/CN107573339A/zh not_active Withdrawn
- 2015-03-05 NZ NZ733234A patent/NZ733234A/en unknown
- 2015-03-05 CA CA2997718A patent/CA2997718A1/en active Pending
- 2015-03-05 US US14/639,916 patent/US9265756B2/en active Active
- 2015-03-05 CN CN201710832497.7A patent/CN107759591A/zh not_active Withdrawn
- 2015-03-05 CN CN201710831795.4A patent/CN107501263A/zh not_active Withdrawn
- 2015-03-05 NZ NZ733225A patent/NZ733225A/en unknown
- 2015-03-05 AU AU2015227064A patent/AU2015227064B2/en active Active
- 2015-03-05 CN CN201710831540.8A patent/CN107501262A/zh active Pending
- 2015-03-05 MX MX2018003837A patent/MX388969B/es unknown
- 2015-03-05 CA CA2997741A patent/CA2997741A1/en not_active Abandoned
- 2015-03-05 CN CN201710831735.2A patent/CN107400132A/zh not_active Withdrawn
- 2015-03-05 RU RU2016139096A patent/RU2638931C1/ru active
- 2015-03-05 PT PT191563691T patent/PT3511000T/pt unknown
- 2015-03-05 PL PL17193737T patent/PL3295941T3/pl unknown
- 2015-03-05 PL PL19156369.1T patent/PL3511000T3/pl unknown
- 2015-03-05 EP EP17193737.8A patent/EP3295941B1/en active Active
- 2015-03-05 CA CA3105571A patent/CA3105571A1/en active Pending
- 2015-03-05 CA CA2997694A patent/CA2997694C/en active Active
- 2015-03-05 CN CN202110197159.7A patent/CN113087705A/zh active Pending
- 2015-03-05 ES ES19156369T patent/ES2919346T3/es active Active
- 2015-03-05 EP EP19156369.1A patent/EP3511000B1/en active Active
- 2015-03-05 NZ NZ724923A patent/NZ724923A/en unknown
- 2015-03-05 CN CN201580002716.8A patent/CN105764508A/zh active Pending
- 2015-03-05 CN CN201710832196.4A patent/CN107759589A/zh active Pending
- 2015-03-05 EP EP19156370.9A patent/EP3520790A1/en not_active Withdrawn
- 2015-03-05 PT PT171937378T patent/PT3295941T/pt unknown
- 2015-03-05 CN CN201710831743.7A patent/CN107540671A/zh not_active Withdrawn
- 2015-03-05 PT PT157585001T patent/PT3113773T/pt unknown
- 2015-03-05 PL PL15758500T patent/PL3113773T3/pl unknown
- 2015-03-05 KR KR1020167024256A patent/KR101697914B1/ko active Active
- 2015-03-05 CN CN201910653673.XA patent/CN110256426A/zh active Pending
- 2015-03-05 TW TW104107082A patent/TWI537270B/zh active
- 2015-03-05 CA CA2997746A patent/CA2997746A1/en not_active Abandoned
- 2015-03-05 EP EP15758500.1A patent/EP3113773B1/en active Active
- 2015-03-05 CA CA3168877A patent/CA3168877A1/en active Pending
- 2015-03-05 CA CA2997692A patent/CA2997692A1/en not_active Abandoned
- 2015-03-05 WO PCT/US2015/019043 patent/WO2015134797A1/en not_active Ceased
- 2015-03-05 DK DK19156369.1T patent/DK3511000T3/da active
- 2015-03-05 CA CA2997697A patent/CA2997697A1/en not_active Abandoned
- 2015-03-05 ES ES17193737T patent/ES2816057T3/es active Active
- 2015-03-05 DK DK15758500T patent/DK3113773T3/da active
- 2015-03-05 KR KR1020177000896A patent/KR101771385B1/ko active Active
- 2015-03-05 CA CA2997703A patent/CA2997703A1/en not_active Abandoned
- 2015-03-05 JP JP2016555827A patent/JP6535683B2/ja active Active
- 2015-03-05 CA CA2941019A patent/CA2941019A1/en not_active Withdrawn
2017
- 2017-11-10 JP JP2017217662A patent/JP2018065819A/ja active Pending

Also Published As

Publication number	Publication date
CA2997692A1 (en)	2015-09-11
PL3295941T3 (pl)	2020-11-16
JP2018065819A (ja)	2018-04-26
EP3520790A1 (en)	2019-08-07
AU2015227064A1 (en)	2016-10-27
CN107759591A (zh)	2018-03-06
WO2015134797A1 (en)	2015-09-11
EP3113773B1 (en)	2019-09-18
ES2919346T3 (es)	2022-07-26
EP3113773A1 (en)	2017-01-11
CA2997694C (en)	2021-04-06
CN107540671A (zh)	2018-01-05
PT3295941T (pt)	2020-08-25
CN110256426A (zh)	2019-09-20
CN107759590A (zh)	2018-03-06
CN107501262A (zh)	2017-12-22
CN107400132A (zh)	2017-11-28
EP3113773A4 (en)	2017-05-10
CN105764508A (zh)	2016-07-13
CA2997746A1 (en)	2015-09-11
CA2997718A1 (en)	2015-09-11
RU2638931C1 (ru)	2017-12-19
KR20170008889A (ko)	2017-01-24
PT3511000T (pt)	2022-05-25
DK3511000T3 (da)	2022-05-30
PL3113773T3 (pl)	2020-05-18
EP3295941A1 (en)	2018-03-21
CA2997741A1 (en)	2015-09-11
AU2015227064B2 (en)	2017-05-11
EP3295941B1 (en)	2020-07-22
PT3113773T (pt)	2019-11-12
MX2016011023A (es)	2016-11-28
US9265756B2 (en)	2016-02-23
KR101771385B1 (ko)	2017-08-24
ES2816057T3 (es)	2021-03-31
EP3511000A1 (en)	2019-07-17
MX367376B (es)	2019-08-16
US20150250774A1 (en)	2015-09-10
CA2997694A1 (en)	2015-09-11
JP6535683B2 (ja)	2019-06-26
TW201538500A (zh)	2015-10-16
CN107573339A (zh)	2018-01-12
CA2997703A1 (en)	2015-09-11
CN107759589A (zh)	2018-03-06
CN113087705A (zh)	2021-07-09
NZ724923A (en)	2018-03-23
CA3168877A1 (en)	2015-09-11
ES2755396T3 (es)	2020-04-22
MX388969B (es)	2025-03-20
PL3511000T3 (pl)	2022-08-22
KR20160106779A (ko)	2016-09-12
DK3113773T3 (da)	2019-11-18
TWI537270B (zh)	2016-06-11
NZ733225A (en)	2018-03-23
CA2997697A1 (en)	2015-09-11
KR101697914B1 (ko)	2017-01-18
NZ733234A (en)	2018-08-31
EP3511000B1 (en)	2022-04-27
CA2941019A1 (en)	2015-09-11
CA3105571A1 (en)	2015-09-11
JP2017507161A (ja)	2017-03-16
CN107501263A (zh)	2017-12-22

Publication	Publication Date	Title
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3372584T5 (da)	2021-05-17	Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse
DK3096741T3 (da)	2020-09-28	Fremgangsmåde til fremstillingen af hybridosomer
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3325443T3 (da)	2022-07-18	Fremgangsmåde til fremstilling af pridopidin
DK3152176T5 (da)	2020-12-21	Fremgangsmåde til fremstillingen af en cementforbindelse
DK3102576T3 (da)	2019-07-22	Dihydropyrrolopyridininhibitorer af ror-gamma
DK3174858T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af pyrazoler
DK3160956T3 (da)	2020-08-31	Inhibitorer af lysin-specifik demethylase-1
DK3294700T3 (da)	2020-04-14	Fremgangsmåde til fremstilling af limonen-4-ol
DK3180331T3 (da)	2022-09-12	Polymorfer af selinexor
DK3511319T3 (da)	2023-07-31	Hæmmere af lysinspecifik demethylase-1
DK3721997T3 (da)	2022-03-28	Fremgangsmåde til fremstilling af en katalysator
DK2953904T3 (da)	2019-07-08	Fremgangsmåde til kontrolleret fremstilling af et biocid
DK3233813T3 (da)	2022-03-07	Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3529233T3 (da)	2020-10-12	Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3277915T3 (da)	2024-01-22	Fremgangsmåde til nedlukning af en brøn
DK3229995T3 (da)	2022-01-17	Fremgangsmåde for fremstilling af et endestykke
DK3295941T3 (da)	2020-08-24	Fremgangsmåde til fremstilling af form a af grapiprant
DK3156539T3 (da)	2022-04-04	Kontinuerlig fremgangsmåde til forbehandling af et ligno-celluloseholdigt råmateriale
DK3262023T3 (da)	2021-02-22	Fremgangsmåde til fremstillingen af diener
DK3137449T3 (da)	2020-03-02	Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
DK3274143T3 (da)	2019-11-25	Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3387086T3 (da)	2022-08-29	Fremgangsmåde til nedlukning af en brønd